王颀, 连臻强, 郭子柏. 乳腺导管原位癌发病率、治疗和预后的系统评价[J]. 循证医学, 2011, 11(3): 148-151. DOI: 10.3969/j.issn.1671-5144.2011.03.015
    引用本文: 王颀, 连臻强, 郭子柏. 乳腺导管原位癌发病率、治疗和预后的系统评价[J]. 循证医学, 2011, 11(3): 148-151. DOI: 10.3969/j.issn.1671-5144.2011.03.015
    WANG Qi, LIAN Zhen-qiang, GUO Zi-bai. Ductal Carcinoma in Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes[J]. Journal of Evidence-Based Medicine, 2011, 11(3): 148-151. DOI: 10.3969/j.issn.1671-5144.2011.03.015
    Citation: WANG Qi, LIAN Zhen-qiang, GUO Zi-bai. Ductal Carcinoma in Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes[J]. Journal of Evidence-Based Medicine, 2011, 11(3): 148-151. DOI: 10.3969/j.issn.1671-5144.2011.03.015

    乳腺导管原位癌发病率、治疗和预后的系统评价

    Ductal Carcinoma in Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes

    • 摘要: DCIS是非浸润乳腺癌, 包括从无生命威胁的低级别病灶到藏匿浸润性乳腺癌病灶的高级别病灶。随着基于钼靶(mammography, MG)检查的乳腺癌筛查的广泛开展, DCIS检出率明显升高, 美国DCIS已占乳腺癌新发病例的25%。目前, DCIS一般被作为浸润性乳腺癌的前躯病变, 但人们对其自然病程仍知之甚少, 因而临床上对DCIS的合理预防和诊治一直存在争议, 本评价文献就相关争议的四个问题进行了解答。

       

    /

    返回文章
    返回